The Discriminating Nature of Dopamine Transporter Image in Parkinsonism: The Competency of Dopaminergic Transporter Imaging in Differential Diagnosis of Parkinsonism: SPECT Study |
Kim, Bom-Sahn
(Departments of Nuclear Medicine, Seoul National University College of Medicine)
Jang, Sung-June (Departments of Nuclear Medicine, Seoul National University College of Medicine) Eo, Jae-Seon (Departments of Nuclear Medicine, Seoul National University College of Medicine) Park, Eun-Kyung (Departments of Nuclear Medicine, Seoul National University College of Medicine) Kim, Yu-Kyeong (Departments of Nuclear Medicine, Seoul National University College of Medicine) Kim, Jong-Min (Departments of Neurology, Seoul National University College of Medicine) Lee, Won-Woo (Departments of Nuclear Medicine, Seoul National University College of Medicine) Kim, Sang-Eun (Departments of Nuclear Medicine, Seoul National University College of Medicine) |
1 | Chui HC, Teng EL, Henderson VW, Moy AC. Clinical subtypes of dementia of the Alzheimer type. Neurology. 1985;35:1544-50 DOI |
2 | Kemppainen N, Ruottinen H, Ngren K, Rinne JO. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology. 2000;55:205-9 DOI ScienceOn |
3 | Ceravolo R, Volterrani D, Gambaccini G, Bernardini S, Rossi C, Logi C, et al. Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study. J Neural Transm. 2004;111: 1065-73. Epub 2004 Jun 18 |
4 | Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology. 2004;60:1568-72 |
5 | McKeith IG. Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol Clin. 2000;18:865-902 DOI |
6 | Kosaka K, Iseki E.: Diffuse Lewy body disease within the spectrum of Lewy body disease. In: Perry R, McKeith I, Perry E (eds): Dementia with Lewy Bodies. New York, Cambridge University Press, 1996, pp 238-47 |
7 | Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with []FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27:867-9 DOI |
8 | Nurmi E, Ruottinen HM, Kaasinen V, Bergman J, Haaparanta M, Solin O, et al. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand []CFT. Ann Neurol. 2000;47:804-8 DOI ScienceOn |
9 | Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with []dopa PET. J Neurol Neurosurg Psychiatry. 1998;64:314-9 DOI |
10 | Morrish PK, Sawle GV, Brooks DJ. An []dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 1996;119:585-91 DOI ScienceOn |
11 | Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003;54: 93-101 DOI ScienceOn |
12 | Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P, et al. Rate of progression in Parkinson's disease: a 6-[]fluoro-L-dopa PET study. Mov Disord. 2001;16:608-15 DOI ScienceOn |
13 | Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in caudate nucleus. J Neurochem. 1991;56:192-8 DOI |
14 | Donnemiller E, Heilmann J, Wenning GK, Berger W, Decristoforo C, Moncayo R, et al. Brain perfusion scintigraphy with -HMPAO or -ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med. 1997;24:320-5 DOI |
15 | Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology. 1985;35:453-61 DOI |
16 | Perneczky R, Msch D, Neumann M, Kretzschmar H, Mller U, Busch R, et al. The Alzheimer Variant of Lewy Body Disease: A Pathologically Confirmed Case-Control Study. Dement Geriatr Cogn Disord. 2005;20:89-94 DOI ScienceOn |
17 | Jeon B, Kim JM, Jeong JM, Kim KM, Chang YS, Lee DS, et al. Dopamine transporter imaging with []--CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease. J Neurol Neurosurg Psychiatry. 1998;65:60-4 DOI |
18 | Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem. 1991;56:192-8 DOI |
19 | O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol. 2004;61:919-25 DOI ScienceOn |
20 | Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. []FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62:133-40 DOI ScienceOn |
21 | Neumeyer JL, Wang SY, Milius RA, Baldwin RM, Zea-Ponce Y, Hoffer PB, et al.[]-2--Carbomethoxy-3--(4-iodo-phenyl)- tropane (-CIT). High affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem. 1991;34:3144-6 DOI |
22 | Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry. 2002;73:134-40 DOI |
23 | Kim SE, Choi JY, Choe YS, Choi Y, Lee WY. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with -beta-CIT SPECT. J Nucl Med. 2003;44:870-6 |
24 | Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's disease striatum. Synapse. 1991;9:43-9 DOI ScienceOn |
25 | Kaufman MJ, and Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum, Synapse. 1991;9;43-9 DOI ScienceOn |
26 | Wang J, Zuo CT, Jiang YP, Guan YH, Chen ZP, Xiang JD, et al. -FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. J Neurol. 2007;254:185-90 DOI |
27 | Booij J, Andringa G, Rijks LJ, Vermeulen RJ, De Bruin K, Boer GJ, et al. []FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTPlesioned monkeys. Synapse. 1997;27:183-90 DOI ScienceOn |
28 | Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, Wolters EC. []FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J Neural Transm. 2001;108:1011-9 DOI |
29 | Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the []-FP-CIT study group. Mov Disord. 2000;15: 503-10 DOI ScienceOn |
30 | Van Laere K, Casteels C, De Ceuninck L, Vanbilloen B, Maes A, Mortelmans L, et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J Nucl Med. 2006;47:384-92 |
31 | Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with Iodine-123-FPCIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med. 1998;39:1879-84 |
32 | Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, et al. Iodine-123-N-omega-fluoropropyl-2-carbomethoxy- 3-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med. 1998;39: 1143-8 |
33 | Pizzolato G, Chierichetti F, Fabbri M, Cagnin A, Dam M, Ferlin G, et al. Reduced striatal dopamine receptors in Alzheimer's disease: single photon emission tomography study with the D2 tracer []-IBZM. Neurology. 1996;47:1065-8 DOI ScienceOn |
34 | de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinsons disease in Europe: the EUROPARKINSON collaborative study. European community concerted action on the epidemiology of Parkinsons disease. J Neurol Neurosurg Psychiatry. 1997;62:10-5 DOI |
35 | Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology. 2000; 55:1540-7 DOI ScienceOn |
36 | Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology. 2001;57: 1497-9 DOI ScienceOn |
37 | Van Laere K, Casteels C, De Ceuninck L, Vanbilloen B, Maes A, Mortelmans L, et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using templatebased discriminant analysis. J Nucl Med. 2006;47:384-92 |
38 | Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-4 DOI |
39 | Colloby S, O'Brien J. Functional imaging in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004;17: 158-63 DOI |